Clinical Trials Browser

Phase 3 × Interventional × Sirolimus × Clear all

NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Phase 3 Active not recruiting

325 enrolled 14 charts

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT00980460 2026-05-04

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Phase 3 Active not recruiting

236 enrolled 18 charts

Gastrointestinal

PRETEXT I Hepatoblastoma

NCT01231412 2026-04-30

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Phase 3 Completed

174 enrolled 12 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00133887 2025-12-26

TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

Phase 3 Completed

Carcinoma, Squamous Cell, Skin Neoplasms

NCT05860881 2025-09-09

SiroSkin

Phase 3 Active not recruiting

Skin Neoplasms

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3 Completed

330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT06929325 2025-04-16

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Phase 3 Not yet recruiting

Breast Neoplasms

NCT03150914 2024-12-24

MILED

Phase 3 Active not recruiting

Lymphangioleiomyomatosis

NCT00414648 2023-11-02

MILES

Phase 3 Completed

89 enrolled 15 charts

Lymphangioleiomyomatosis

NCT05534672 2023-08-08

RaRE-TS

Phase 3 Recruiting

Drug Resistant Epilepsy, Epilepsy, Tuberous Sclerosis

NCT00406393 2023-01-04

BMT CTN 0402

Phase 3 Completed

304 enrolled 20 charts

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04736589 2021-02-03

Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Phase 3 Not yet recruiting

Breast Neoplasms

NCT00382109 2019-08-07

Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission

Phase 3 Completed

146 enrolled 14 charts

LymphoidOther hematologic neoplasm

Graft vs Host Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03298958 2019-06-12

Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer

Phase 3 Withdrawn

Urinary Bladder Neoplasms

NCT00928018 2019-02-01

Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma

Phase 3 Completed

139 enrolled 11 charts

Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT03140449 2017-05-04

Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis

Phase 3 Completed

Tuberous Sclerosis

NCT00355862 2014-07-30

Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma

Phase 3 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT00928798 2012-03-08

Topical Rapamycin for Fibrofolliculomas

Phase 3 Completed

Birt-Hogg-Dube Syndrome

NCT00554125 2007-11-06

Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria

Phase 3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular